Multicellular living organisms and unmodified parts thereof and – Nonhuman animal – Transgenic nonhuman animal
Reexamination Certificate
2004-04-23
2009-06-09
Montanari, David (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Nonhuman animal
Transgenic nonhuman animal
C800S003000, C800S008000, C800S014000
Reexamination Certificate
active
07544855
ABSTRACT:
In accordance with the present invention, it is demonstrated that selected mutations such as an Asp->Ala (D664A) mutation in APP (which prevents cleavage at the caspase cleavage site) prevent both hippocampal synaptic loss and dentate gyral atrophy, even though such mutations do not interfere with the production of Aβ or the formation of amyloid plaques in a transgenic model of Alzheimer's disease. Accordingly, in view of this finding, methods have been developed for the identification of agents which block cleavage at Asp664 of APP, including transgenic animals which are useful for such purpose, as well as methods for the use thereof for the treatment of neurodegenerative diseases.
REFERENCES:
patent: 4046722 (1977-09-01), Rowland
patent: 4631190 (1986-12-01), Shen et al.
patent: 4701521 (1987-10-01), Ryser et al.
patent: 4847240 (1989-07-01), Ryser et al.
patent: 5144011 (1992-09-01), Shen et al.
patent: 5149796 (1992-09-01), Rossi et al.
patent: 5176996 (1993-01-01), Hogan et al.
patent: 5222982 (1993-06-01), Ommaya
patent: 5225337 (1993-07-01), Robertson et al.
patent: 5225347 (1993-07-01), Goldberg et al.
patent: 5246921 (1993-09-01), Reddy et al.
patent: 5256775 (1993-10-01), Froehler
patent: 5264564 (1993-11-01), Matteucci
patent: 5268164 (1993-12-01), Kozarich et al.
patent: 5387742 (1995-02-01), Cordell
patent: 5455169 (1995-10-01), Mullan
patent: 5795963 (1998-08-01), Mullan
patent: 5877015 (1999-03-01), Hardy et al.
patent: 6005004 (1999-12-01), Katz et al.
patent: 6051684 (2000-04-01), McDonlad et al.
patent: 6300540 (2001-10-01), Hardy et al.
patent: 6689784 (2004-02-01), Bebbington et al.
patent: 6818448 (2004-11-01), Mullan
patent: 2004/0192889 (2004-09-01), Bredesen
patent: WO 88/09810 (1988-12-01), None
patent: WO 89/01034 (1989-11-01), None
patent: WO 93/09236 (1993-05-01), None
patent: WO 98/15828 (1998-04-01), None
patent: WO 98/15828 (1998-04-01), None
patent: WO 02/092788 (2002-11-01), None
patent: WO 02/092788 (2002-11-01), None
Houdebine LM, The methods to generate transgenic animals and to control transgene expression, 2002, J. of Biotechnology, vol. 98, pp. 145-160.
Smith KR, Gene transfer in higher animals: theoretical considerations and key concepts, J. of Biotechnology, vol. 99, pp. 1-22.
Ristevski S, Making better transgenic models, 2005, Molecular Biotechnology, vol. 29, pp. 153-163.
Montoliu L, Gene transfer strategies in animal transgenesis, 2002, Cloning and Stem Cells, vol. 4, pp. 39-46.
Echeverria et al., Rat transgenic models with a phenotype of intracellular Abeta accumulation in hippocampus and cortexJ Alzheimers Dis. Jun. 2004;6(3):209-19.
Yang T., 2004, Am J Physiol Renal Physiol, vol. 288, pp. F1125-F1132.
Dansky HM, 1999, Arterioscler Thromb Vasc Biol, vol. 19, pp. 1960-1968.
Crabbe et al., 1999, Science, vol. 284, pp. 1670-1672.
Dodart, J. C. et al., Neuroanatomical Abnormalities in Bahaviorally Characterized APPV/1/FTransgenic Mice, Neurobiol Dis 7:71-85 (2000).
Galvan et al., Caspase cleavage of members of the amyloid precursor family of proteins, J Neurochem 82:283-94 (2002).
Gautier et al., α-DNA IV: α-anomeric and β-anomeric tetrathymidylates covalently linked to intercalating oxazoloyridpyridocarbazole. Synthesis, physicochemical properties and poly (rA) binding,Nucl. Acids Res.15:6625-6641 (1987).
Gervais et al. Involvement of Caspases in Proteolytic Cleavage of Alzheimer's Amyloid-β Precursor Protein and Amyloidogenic Aβ Peptide Formation, Cell, 97:395-406 (1999).
Gonzalez-Lima et al., Reduced corpus callosum, fomix and hippocampus in PDAPP transgenic mouse model of Alzheimer's disease. Clinical Neuroscience and Neuropathology, 12(118):2375-2379 (2001).
Hsia, A. Y. et al., Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models,Proc Natl Acad Sci USA96:3228-33 (1999).
Holtzman et al., Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease, Proc. Natl. Adad. Sci., 97(6):2892-2897 (2000).
Inoue et al., Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and Rnase H, FEBS Lett. 215:327-330 (1987).
Inoue et al., Synthesis and hybridization studies on two complementary nona(2′-O-methyl)ribonucleotides,Nucl. Acids Res.15:6131-6148 (1987).
Jin, K. et al., Increased hippocampal neurogenesis in Alzheimer's disease, Proc. Natl. Acad. Sci. USA 101:343-7 (2004).
Lemaitre et al., Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site,Proc. Natl. Acad. Sci.USA 84:648-652 (1987).
Letsinger et al., Cholesteryl-conjugated oligonucleotides: Synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture,Proc. Natl. Acad. Sci.U.S.A. 86:6553-6556 (1989).
Li, Y. et al., Targeted expression of human CuZn superoxide dismutase gene in mouse central nervous system, J Neurosci Methods 89, 49-55 (1999).
Lu et al., Amyloid β Protein Toxicity Mediated by the Formation of Amyloid-β Protein Precursor Complexes, Ann. Neurol., 54:781-789 (2003).
McManus, et al., Gene Silencing in Mammals by Small Interfering RNAs,Nature Reviews Genetics3:737 (2002).
Miller, A. D., “Human gene therapy comes of age,”Nature357:455-460 (1992).
Mucke, et al., “High-Level Neuronal Expression of Aβ1-42in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation,” The Journal of Neuroscience, 20(11):4050-4058 (2000).
Rubin, Emmanuel, Editor, “The Nervous System,” Pathology, 3rded., pp. 1492-1496 (1999).
Rubin, Emmanuel, Editor, “Amyloidosis,” Pathology, 3rded., p. 1226 (1999).
Perreault, et al., Mixed deoxyribo- and ribo- oligonucleotides with catalytic activity,Nature, 344:565-567 (1990).
Redwine, J. M. et al., Dentate gyrus volume is reduced beore onset of plaque formation in PDAPP mice: A magnetic resonance microscopy and stereologic analysis, Proc Natl Acad Sci USA 100:1381-6 (2003).
Selkoe, D. J., Alzheimer's Disease Is a Synaptic Failure, Science, 298:789-791 (2002).
Soriano et al., The amyloidogenic pathway of Amyloid Precursor Protein (APP) Is Independent of Its Ceavage by Caspaces, J. Biol. Chem., 276(31):29045-29050 (2001).
Van der Krol et al., Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences, BioTechniques 6:958-976 (1988).
Weggen, et al, A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity, Nature 414:212-6 (2001).
Wyss-Coray, T. et al., Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease,-Nature 389:603-6 (1997).
Zon, G., Oligonucleotide Analogues as Potential Chemotherapeutic Agents,Pharm. Res. 5:539-549 (1988).
Anonymous. (e-pub. Mar. 7, 2008). “Memory Loss in Hyperactive State With Alzheimer's Study Suggests Brains of Patients Get Stuck in Memory-Deletion Mode,”U.S. News&Word Report, located at http://health.usnews.com/usnews/health/healthday/080307/memory-loss-in-hyperactive-state-with-alzheimers.htm>, last visited on Mar. 24, 2008, two pages.
Banks, W.A. et al. (1992). “Bidirectional Passage of Peptides Across the Blood-Brain Barrier,” Chapter 21 inCircumventricular Organs and Brain Fluid Environment: Molecular and Functional Aspects, Ermisch, A. et al. eds., Elsevier Science Publishers B.V.: Amsterdam, pp. 139-148.
Banwait, S. (Feb. 2008). “C-Terminal Cleavage of the Amyloid-β Protein Precursor at Asp664: A Switch Associated with Alzheimer's Disease,”J. Alzheimers Dis. 13(1):1-16.
Barnes, N.Y. et al. (Aug. 1, 1998). “Increased Production of Amyloid Precursor Protein Provides a Substrate for Caspase-3 in Dying Motoneurons,”J. Neurosci. 18(15):5869-5880.
Bobo, R.H. et al. (Mar. 1994). “Convection-Enhanced Delivery of Macromolecules in the Brain,”Proc. Natl. Acad. Sci. USA91: 2076-2080.
Bredesen, D.E. (Dec. 1995). “Neural Apoptosis,&#x
Bredesen Dale E.
Galvan Veronica
Buck Institute
Montanari David
Morrison & Foerster / LLP
LandOfFree
Transgenic mouse whose genome comprises an APP having a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transgenic mouse whose genome comprises an APP having a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenic mouse whose genome comprises an APP having a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4081117